Antidote
FEBRUARY 21, 2024
While effectively recruiting patients is a necessary part of every study, it can also incur significant costs. Patient recruitment is one of the largest budget categories in a clinical trial , but often, this is due to ineffective outreach methods and expensive screen failures that contribute to excessive spending.
pharmaphorum
FEBRUARY 21, 2024
Clinical research involves trial and error as part of the drug development process. Learn more about how to optimise drug trials and the important role of participants in clinical research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
FEBRUARY 21, 2024
Black participation in clinical trials, and the underrepresentation of minority groups in general in trials, remains low. This lack of diversity can lead to skewed results that may not accurately reflect the efficacy of medical interventions across all populations. It is therefore important to work towards increasing Black participation in clinical trials, which begins with understanding the barriers to participation and taking steps to address them.
ACRP blog
FEBRUARY 22, 2024
When the ACRP Certified Professional (ACRP-CP®) certification launched in 2017, it made available to the clinical research field a rigorously developed and validated test leading to a credential highlighting the skills of professionals whose job roles do not easily stay within the boundaries of traditional clinical research coordinators (CRCs), clinical research associates (CRAs), or principal investigators.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Worldwide Clinical Trials
FEBRUARY 21, 2024
During clinical development, new chemical entities (NCEs) require an absorption, metabolism, and excretion (AME) study. Also known as a human radiolabeled mass balanced study, the AME study aims to determine the overall metabolism and excretion pathways of the NCE, as well as to identify and quantify circulating metabolites relative to parent or total drug-related exposure.
Rethinking Clinical Trials
FEBRUARY 22, 2024
An updated template from the NIH Pragmatic Trials Collaboratory provides guidance for the transparent reporting of the primary results of pragmatic clinical trials. The template includes elements from the Consolidated Standards of Reporting Trials (CONSORT) and its extensions. It also addresses secondary use of electronic health record data, involvement of research partners and healthcare systems in the conduct of pragmatic trials, and special ethical and regulatory considerations.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Antidote
FEBRUARY 22, 2024
Behind every new treatment is the incredible team of doctors, researchers, patients, and clinical trial specialists who worked on the research that made it possible. Because every therapy must be rigorously tested through clinical trials before it can be approved, the process from creation to entering the market can be an arduous one — but it’s one that makes medical breakthroughs possible.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 20, 2024
The Indian Institute of Science (IISc) and Blockchain For Impact (BFI) have teamed up to maximise translational research projects where the latter aims to allocate US$1 million. The collaboration, under the BFI-Biome Virtual Network Programme, will see BFI to support various research projects at the IISc.
Rethinking Clinical Trials
FEBRUARY 21, 2024
In this Friday’s PCT Grand Rounds, Adrian Hernandez and Christopher Lindsell of Duke University will present “Virtual Vigilance: Monitoring of Decentralized Clinical Trials.” The Grand Rounds session will be held on Friday, February 23, 2024, at 1:00 pm eastern. Hernandez is the executive director of the Duke Clinical Research Institute (DCRI) and professor of medicine and vice dean in the Duke University School of Medicine.
Bio Pharma Dive
FEBRUARY 21, 2024
The full results spotlight cell therapy’s potential to treat lupus and other inflammatory conditions, but also the problems drug developers must solve first.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
FEBRUARY 22, 2024
The company will evaluate an IMC-F106C/Opdivo combination treatment in a Phase III registrational study called PRISM-MEL-301.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 22, 2024
Some form of brain injury could be behind the symptoms reported by those with long COVID, according to a new study, and adapting tests and treatments to match could aid progress in tackling the condition.
Pharma Times
FEBRUARY 20, 2024
The nanogels, in combination with rolipram, contributed to the recovery of injured tissue
Bio Pharma Dive
FEBRUARY 22, 2024
The startup’s Series C round will support a clinical-stage drug the company thinks could address some of the weaknesses of other KRAS-targeting medicines.
Pharmaceutical Technology
FEBRUARY 23, 2024
The FDA Office of Generic Drugs reported a rise in generic drug approvals, as several first-time generics entered the market.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 22, 2024
In its efforts to streamline and rationalise the sampling procedure and maintain a centralised monthly database the Central Drugs Standard Control Organisation (CDSCO) has released the final version of the regulatory guidelines for sampling of drugs, cosmetics and medical devices by drugs inspectors of the Central and State drug authorities.
Pharma Times
FEBRUARY 22, 2024
The trial is recruiting patients in Leeds, Manchester, Oxford, London, Cambridge and Kent
Bio Pharma Dive
FEBRUARY 23, 2024
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
FEBRUARY 22, 2024
The FDA has accepted Regeneron’s biologics licence application (BLA) for linvoseltamab to treat multiple myeloma for priority review.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 18, 2024
If you ask 50 different people how long the effects of cannabis last, you’re likely to get 50 different answers. This can be a problem for figuring out how long a patient using the drug for medical purposes is going to remain impaired. A meta-analysis of 80 papers published in 2021 narrowed down this timeframe.
Pharma Times
FEBRUARY 23, 2024
The immunosuppressant reduced inflammation in patients with the skin condition after three days
Bio Pharma Dive
FEBRUARY 20, 2024
The biotech set a price of roughly $515,000 per patient for its therapy Amtagvi, the first to be approved based on a decades-old technique of using tumor-infiltrating lymphocytes.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 21, 2024
Approximately 1 in 26 people develop epilepsy, a condition in which someone experiences recurring and unprovoked seizures. But experiencing a seizure does not always mean a person has epilepsy. Seizures can be provoked by acute head injuries, alcohol withdrawal and high blood sugar, among other things.
Pharma Times
FEBRUARY 21, 2024
Results showed robust responses in patients with pancreatic and colorectal cancer
Bio Pharma Dive
FEBRUARY 21, 2024
One expert views Amtagvi’s approval as a catalyst for further investment in TIL therapies, akin to how Kymriah’s 2017 clearance buoyed CAR-T treatment.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
FEBRUARY 20, 2024
Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 19, 2024
A detailed look at minute differences in the levels of specific proteins in blood has allowed researchers to identify potential early warning signs of dementia.
Pharma Times
FEBRUARY 23, 2024
In England, around 1,100 cases of bowel cancer are caused by the inherited condition every year
Bio Pharma Dive
FEBRUARY 23, 2024
European drug regulators recommended clearing J&J and Legend Biotech's Carvykti for use as early as after first relapse, potentially giving the therapy an advantage over Bristol Myers’ Abecma.
Expert insights. Personalized for you.
52 
Let's personalize your content